Summary:
- This preprint study investigates the effectiveness of a new COVID-19 vaccine candidate called "Covax-19" in a large-scale clinical trial.
- The results show that the Covax-19 vaccine demonstrated high efficacy in preventing symptomatic COVID-19 infections, with a 92% reduction in cases compared to the placebo group.
- The vaccine was also found to be safe, with no serious adverse events reported, and it induced a robust immune response in participants across different age groups.